Paris - Delayed Quote EUR

Sanofi (SAN.PA)

91.95

+4.25

(+4.85%)

As of 4:27 PM GMT+2. Market Open.

AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.

Investor's Business Daily 12 minutes ago

AZN

SNY

CELG-RT
Sanofi Sales, Profit Beat Expectations

Sanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus, with sales growth driven by continued strength in anti-inflammatory drug Dupixent and its new drug launches.

The Wall Street Journal 7 hours ago

SNY

SNYNF
UPDATE 2-Sanofi profit slips on generic competition and currency effects

Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.

Reuters 8 hours ago

SNY
Sanofi profit slips on generic competition and currency effects

(Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.

Reuters 9 hours ago

SNY
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performa

GlobeNewswire 9 hours ago

SNY

SNYNF
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

Zacks yesterday

ABBV

SNY

CELG-RT
Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff

(Bloomberg) -- French drugmaker Sanofi has asked banks to pitch for roles on the separation of its consumer-health business, according to people familiar with the matter, one of the biggest deals likely to happen in Europe this year. Most Read from BloombergTaylor Swift Is Proof That How We Critique Music Is BrokenBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsBiden’s New Chopper Is Demoted After Scorching White House LawnTesla Soars as Musk’s Cheaper EVs Calm Fears Ove

Bloomberg yesterday

SNY
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

Zacks yesterday

SNY
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi’s robust immunology pipeline and a testament to Sanofi’s ability to successfully accele

GlobeNewswire 2 days ago

SNY

SNYNF
Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer

Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer

PREMIUM
MT Newswires 2 days ago

SNY
Sanofi to overhaul US operations of vaccines, cut jobs

Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the timeframe and the number of employees to be impacted. Sanofi CEO Paul Hudson has been trying to build investor confidence in the company's drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending. The company's vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.

Reuters 6 days ago

SNY
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS

GlobeNewswire 8 days ago

SNY

SNYNF
Sanofi: Information concerning the total number of voting rights and shares - March 2024

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi

GlobeNewswire 12 days ago

SNY

SNYNF
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

COMBINED GENERAL MEETING OF APRIL 30, 2024 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Thursday April 30, 2024 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris. The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the we

GlobeNewswire 16 days ago

SNY

SNYNF
10 Best Weight Loss Drug Stocks to Buy Now

In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]

Insider Monkey 18 days ago

LLY

NVO

VKTX
UPDATE 2-Cyclicals drive modest gains across European stocks

The continent-wide STOXX 600 index closed up 0.2%, led by a 1.7% gain in the basic resources sector as copper prices hit their highest in more than 14 months. "Recent inflation trends in Europe stand in stark contrast to what is happening in the U.S.," as per strategists at BCA Research. "This divergence in inflationary dynamics will force the ECB to be more dovish than the Fed."

Reuters 21 days ago

SNY
Sanofi to Settle Claims That Heartburn Drug Zantac Caused Cancer

The French healthcare company said the deal would require the consent of individual plaintiffs and would take time to conclude.

The Wall Street Journal 21 days ago

SNY

SNYNF
UPDATE 2-Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday. Sanofi did not disclose the financial terms of the deal. The agreement, which still needs to be finalized, will resolve most of the lawsuits against the French pharmaceutical company in U.S. state courts, with the exception of Delaware where the majority of the cases are pending.

Reuters 21 days ago

SNY
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 27 days ago

DNLI

SNY

HALO
32 Countries with the Highest Rates of Diabetes

In this article, we will be taking a look at the 32 countries with the highest rates of diabetes. If you do not want to learn about the global diabetes market, head straight to the 5 Countries with the Highest Rates of Diabetes. The Global Diabetes Market and Its Implications The global diabetes market is […]

Insider Monkey 30 days ago

SNY

NVO

Performance Overview

Return	SAN.PA	CAC 40
YTD	+2.44%	+6.01%
1-Year	-7.23%	+5.58%
3-Year	+20.74%	+27.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi (SAN.PA)

AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

Sanofi Sales, Profit Beat Expectations

UPDATE 2-Sanofi profit slips on generic competition and currency effects

Sanofi profit slips on generic competition and currency effects

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer

Sanofi to overhaul US operations of vaccines, cut jobs

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

Sanofi: Information concerning the total number of voting rights and shares - March 2024

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

10 Best Weight Loss Drug Stocks to Buy Now

UPDATE 2-Cyclicals drive modest gains across European stocks

Sanofi to Settle Claims That Heartburn Drug Zantac Caused Cancer

UPDATE 2-Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

32 Countries with the Highest Rates of Diabetes

Performance Overview